The FDA and IBS drug development.
Mangel
Allen W
AW
D000527:Alprostadil / Q000031:analogs & derivatives / Q000627:therapeutic use; D018118:Chloride Channels; D002986:Clinical Trials as Topic / Q000379:methods*; D003226:Congresses as Topic; D017277:Drug Approval; D004341:Drug Evaluation / Q000379:methods*; D004415:Dyspepsia / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000188:drug therapy*; D000068238:Lubiprostone; D014481:United States; D014486:United States Food and Drug Administration; D014922:Wisconsin
D018118:Chloride Channels; D005765:Gastrointestinal Agents; D000068238:Lubiprostone; D000527:Alprostadil